61 – 70 of 72
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2011
-
Mark
Gemcitabine Plus Docetaxel Versus Docetaxel in Patients With Predominantly Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer: A Randomized, Phase III Study by the Danish Breast Cancer Cooperative Group
- Contribution to journal › Article
- 2010
-
Mark
Parametric Response Map as a Potential Imaging biomarker for Distinguishing Progression fromPseudo-progression in High Grade gliomas.
- Contribution to journal › Article
-
Mark
Finasteride to prevent prostate cancer : Should all men or only a high-risk subgroup be treated?
- Contribution to journal › Article
- 2009
-
Mark
In reply
- Contribution to journal › Letter
-
Mark
Pretreatment prostate-specific antigen (PSA) velocity and doubling time are associated with outcome but neither improves prediction of outcome beyond pretreatment PSA alone in patients treated with radical prostatectomy
- Contribution to journal › Article
-
Mark
Systematic review of Pretreatment prostate-specific antigen velocity and doubling time as predictors for prostate cancer
- Contribution to journal › Article
- 2008
-
Mark
Concordance of survival in family members with prostate cancer
- Contribution to journal › Article
- 2005
-
Mark
The cost-effectiveness of post-operative radiotherapy after breast conservation surgery in stage I-II breast cancer in Sweden
- Contribution to journal › Published meeting abstract
- 2004
-
Mark
Hyperthermic intraperitoneal chemotherapy in patients with peritoneal carcinosis (multiple letters)
- Contribution to journal › Letter
- 2003
-
Mark
Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer
(2003) In Journal of clinical oncology : official journal of the American Society of Clinical Oncology 21(20). p.43-3737
- Contribution to journal › Article
